[Skip to Content]
[Skip to Content Landing]
Editorial
July 5, 2016

Deutetrabenazine for Treatment of Chorea in Huntington Disease

Author Affiliations
  • 1University of California, San Francisco
 

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2016;316(1):33-35. doi:10.1001/jama.2016.8011

In this issue of JAMA, the Huntington Study Group (HSG), First-HD study investigators, reports findings from a randomized trial examining use of a deuterated form of tetrabenazine, called deutetrabenazine, for treatment of chorea in patients with Huntington disease.1 Tetrabenazine, a vesicular monoamine transporter type 2 inhibitor that depletes monoamines including dopamine, is used worldwide for the treatment of chorea and dystonia. Tetrabenazine was approved by the US Food and Drug Administration (FDA) for the treatment of chorea in Huntington disease, based on a prior HSG study.2

×